---
title: "Ocrevus (ocrelizumab) in multiple sclerosis: Storage and supply questions"
description: "Storage and supply questions on Ocrevus (ocrelizumab) in multiple sclerosis, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Topics: Storage. Questions: How is Ocrevus Zunovo supplied and stored? How is Ocrevus IV prepared and stored? 2 questions quoted from 3 sources."
canonical: "https://www.evicenter.com/medical-information/ocrevus--multiple-sclerosis/storage-and-supply"
published: "2026-11-12T22:05:36-05:00"
modified: "2026-11-14T15:19:23-05:00"
---

# Ocrevus (ocrelizumab) in multiple sclerosis: Storage and supply questions

Manufacturer: Genentech, Inc.  
Prescribing information: [Ocrevus](https://www.gene.com/download/pdf/ocrevus_prescribing.pdf), [Ocrevus Zunovo](https://www.gene.com/download/pdf/ocrevus_zunovo_prescribing.pdf)

Storage and supply questions that apply to every indication of Ocrevus are on [Ocrevus (ocrelizumab), all indications: Storage and supply](https://www.evicenter.com/medical-information/ocrevus/storage-and-supply).

## Storage

<a id="ocrevus-zunovo-storage"></a>

### How is Ocrevus Zunovo supplied and stored?

Applies to: Relapsing forms of multiple sclerosis and primary progressive multiple sclerosis in adults (OCREVUS ZUNOVO subcutaneous)

> “OCREVUS ZUNOVO (ocrelizumab and hyaluronidase-ocsq) injection for subcutaneous use is a sterile, 
> preservative-free, clear to slightly opalescent, and colorless to pale brown solution supplied as a carton containing 
> one 920 mg and 23,000 units/23 mL (40 mg and 1,000 units/mL) single-dose vial (NDC 50242-554-01).”

Source: [OCREVUS: OCREVUS ZUNOVO, page 21, captured 2026-11-12](https://www.gene.com/download/pdf/ocrevus_zunovo_prescribing.pdf#page=21)

> “Storing OCREVUS ZUNOVO before use<sup>1</sup>:
> Store OCREVUS ZUNOVO vials at 2°C to 8°C (36°F to 46°F) in the original carton to protect from light
> Do not freeze or shake
> If necessary, OCREVUS ZUNOVO can be removed and placed back into the refrigerator. The total combined time out of the refrigerator for the unopened OCREVUS ZUNOVO vial must not exceed 12 hours at 25°C (77°F)
> Storing the syringe if dose is not used immediately<sup>1</sup>:
> Use aseptic technique to withdraw the entire OCREVUS ZUNOVO contents from the vial into the syringe to account for the dose volume (23 mL) plus the priming volume. Replace the transfer needle with a syringe closing cap. DO NOT attach a winged SC infusion set
> The closed syringe can be refrigerated (2°C to 8°C [36°F to 46°F]) for up to 72 hours, followed by 8 hours at ambient temperatures (<25°C [77°F]) in diffuse daylight
> If the prepared syringe was stored at 2°C to 8°C (36°F to 46°F), allow the syringe to acclimate to room temperature prior to administration”

Source: [OCREVUS: Dosing, captured 2026-11-12](https://www.ocrevus-hcp.com/ocrevus-zunovo/dosing-administration.html#:~:text=Storing%20OCREVUS%20ZUNOVO%20before,room%20temperature%20prior%20to%20administration)

This passage is in a collapsed section of the page; select: STORING OCREVUS ZUNOVO

<a id="ocrevus-iv-preparation-storage"></a>

### How is Ocrevus IV prepared and stored?

Applies to: Relapsing forms of multiple sclerosis and primary progressive multiple sclerosis in adults (OCREVUS intravenous)

> “OCREVUS must be prepared by a healthcare professional using aseptic technique
> Visually inspect for particulate matter and discoloration prior to administration. Do not use the solution if discolored or if the solution contains discrete foreign particulate matter. Do not shake
> Withdraw intended dose and further dilute into an infusion bag containing 0.9% sodium chloride injection to a final drug concentration of approximately 1.2 mg/mL
> Withdraw 10 mL (300 mg) of OCREVUS and inject into 250 mL
> Withdraw 20 mL (600 mg) of OCREVUS and inject into 500 mL
> Do not use other diluents to dilute OCREVUS since their use has not been tested. The product contains no preservative and is intended for single use only
> Prior to the start of the intravenous infusion, the contents of the infusion bag should be at room temperature
> Use the prepared solution immediately. If not used immediately, store up to 24 hours in the refrigerator at 2°C to 8°C (36°F to 46°F) and 8 hours at room temperature up to 25°C (77°F), which includes infusion time. In the event an intravenous infusion cannot be completed the same day, discard the remaining solution
> No incompatibilities between OCREVUS and polyvinyl chloride or polyolefin bags and intravenous administration sets have been observed”

Source: [OCREVUS: Dosing and Administration, captured 2026-11-12](https://www.ocrevus-hcp.com/ocrevus/dosing-administration.html#:~:text=OCREVUS%20must%20be%20prepared%20by,administration%20sets%20have%20been%20observed)

## Related pages
- [Medical information: Ocrevus (ocrelizumab): Multiple sclerosis](https://www.evicenter.com/medical-information/ocrevus--multiple-sclerosis)
- [Indication](https://www.evicenter.com/medical-information/ocrevus--multiple-sclerosis/indication)
- [Pharmacology](https://www.evicenter.com/medical-information/ocrevus--multiple-sclerosis/pharmacology)
- [Clinical trials](https://www.evicenter.com/medical-information/ocrevus--multiple-sclerosis/clinical-trials)
- [Real-world evidence](https://www.evicenter.com/medical-information/ocrevus--multiple-sclerosis/real-world-evidence)
- [Safety](https://www.evicenter.com/medical-information/ocrevus--multiple-sclerosis/safety)
- [Specific populations](https://www.evicenter.com/medical-information/ocrevus--multiple-sclerosis/specific-populations)
- [Drug interactions](https://www.evicenter.com/medical-information/ocrevus--multiple-sclerosis/drug-interactions)
- [Dosing and administration](https://www.evicenter.com/medical-information/ocrevus--multiple-sclerosis/dosing-and-administration)
